Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients
American Journal of Kidney Diseases — Broseta JJ, Rodríguez-Espinosa D, Rodríguez N, et al. | June 24, 2021
Researchers conducted an observational prospective, multi-center cohort study with the aim to evaluate the humoral and cellular responses to messenger RNA (mRNA) SARS-CoV-2 vaccines in patients with kidney failure requiring maintenance dialysis. Vaccination of 205 patients treated at three dialysis units at the Hospital Clínic of Barcelona (Spain) was done from February 3 to April 4, 2021 and their follow up was done until April 23, 2021. A response (humoral, cellular, or both) developed in 97.7% of 175 vaccinated patients who were seronegative at baseline. This suggests a high proportion of patients with kidney failure receiving maintenance dialysis exhibit generation of a humoral and cellular immune response. These observations along with the high risk of infection and poor clinical outcomes among these patients make their vaccination a health priority.